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ABSTRACT
Objectives: To explore the influence of overdiagnosis
information on women’s decisions about
mammography.
Design: A qualitative focus group study with
purposive sampling and thematic analysis, in which
overdiagnosis information was presented.
Setting: Community and university settings
in London.
Participants: 40 women within the breast screening
age range (50–71 years) including attenders and non-
attenders were recruited using a recruitment agency as
well as convenience sampling methods.
Results: Women expressed surprise at the possible
extent of overdiagnosis and recognised the
information as important, although many struggled to
interpret the numerical data. Overdiagnosis was viewed
as less-personally relevant than the possibility of
‘under diagnosis’ (false negatives), and often
considered to be an issue for follow-up care
decisions rather than screening participation. Women
also expressed concern that information on
overdiagnosis could deter others from attending
screening, although they rarely saw it as a deterrent.
After discussing overdiagnosis, few women felt that
they would make different decisions about breast
screening in the future.
Conclusions: Women regard it as important to be
informed about overdiagnosis to get a complete picture
of the risks and benefits of mammography, but the
results of this study indicate that understanding
overdiagnosis may not always influence women’s
attitudes towards participation in breast screening.
The results also highlight the challenge of
communicating the individual significance of
information derived from population-level modelling.
INTRODUCTION
The controversy over the risks and beneﬁts
of breast cancer screening has been played
out in the public media1 as well as the
medical press.2–5 It prompted an independ-
ent review of the research evidence on breast
cancer screening in the UK6 which reported
its ﬁndings in October 2012.7 As part of the
debate, the information about breast screen-
ing provided by the National Health Service
(NHS) has been criticised as being one-
sided.8 A key concern is that the risk of over-
diagnosis is not adequately reﬂected in the
information that is given to the public.9–12
However, given the complexity of interpret-
ing results obtained from modelling popula-
tion patterns of screening and mortality, and
the difﬁculties of applying population-level
results to individual decision-making, there
may be challenges in communicating this
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▪ Little is known about the impact that information
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might have on women’s decision-making about
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responses to information on overdiagnosis in
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that women should be informed about it.
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it as an issue for treatment, rather than screening
decisions.
▪ Few women felt that the information they had been
given would affect their future breast screening
decisions.
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▪ This is the first study to explore responses to
overdiagnosis in breast screening in the UK and
benefitted from the use of in-depth qualitative
methods.
▪ The use of the phrase ‘slow-growing cancer’ in our
explanation of overdiagnosis may have affected
women’s responses.
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information, particularly given the range of estimates
about the risk of overdiagnosis. The UK review reported
estimates between 9.7% and 29.4% across three trials,7
depending on the denominator used, and other studies
have reported higher and lower ﬁgures.3
At present it is unclear whether women would like to
have numerical information on overdiagnosis and
whether they would take it into account in making breast
screening decisions. Survey results in the USA and
Europe have indicated considerable enthusiasm for
screening and a tendency for the public to overestimate
the beneﬁts of mammography.13 14 Tolerance of false-
positive results also seems high, with one US study
ﬁnding that even among women who had experienced a
false-positive mammogram, a third believed that it would
be acceptable for 10 000 women or more to have false-
positive results to save one life from breast cancer.15 The
issue of overdiagnosis and unnecessary treatment is prob-
ably less well understood by the public. The same US
study found that only 7% of women were aware of non-
progressive breast cancer, but after a brief explanation of
ductal carcinoma in situ and the risk of overtreatment,
60% wanted to take this information into account when
deciding about mammography screening.15 This indi-
cates the importance of providing information on over-
diagnosis, although in the survey context only a very brief
description could be given. It is possible that immediate
responses to survey questions on a previously unfamiliar
topic may lack ecological validity and could be thought of
as ‘non-attitudes’ in that they do not reﬂect any pre-
existing beliefs.16 This problem could be addressed by
creating an opportunity for women to discuss and reﬂect
on their understanding of overdiagnosis and the poten-
tial impact of this information on subsequent screening
decisions in a more considered and ecologically valid way.
In a recent UK survey of the public’s preferences for
information on cancer screening (in this case it was
colorectal cancer), most people, responding on a scale
of 1–10, said they would like all available information
about risks of screening as well as beneﬁts.17 However,
when asked more detailed and open questions in quali-
tative research, the UK public can be critical when risk
information is included in colorectal screening informa-
tion leaﬂets; arguing that if the NHS thinks people
should go for screening, they should give unambiguous
messages and not ‘frighten people off’ with stories of
rare risks and the complexities of follow-up.18 Some
studies have also found women to be suspicious about
the motivation behind questioning the beneﬁts of mam-
mography.19 To take forward new approaches to the pro-
vision of breast screening information, it is crucial to
gain an understanding of women’s perspective on the
idea of ‘overdiagnosis’. Information must be provided in
a manner that is understandable and not likely to under-
mine equality of access.
Within the current debate about overdiagnosis, the
voice of the users of the screening programme, women
themselves, has been largely silent. The one study to
date examined Australian women’s responses to detailed
information on overdiagnosis and a range of estimates
of its prevalence, using focus group methodology.20 The
results showed that although women generally lacked
prior awareness of the issue, they were able to under-
stand it when information was provided in the form on
an audiovisual presentation. The impact of the informa-
tion on future screening intentions varied widely
between women and was also different depending on
the prevalence of overdiagnosis presented.
The present study aimed to use qualitative methods to
elicit British women’s reactions to the notion of over-
diagnosis and examine the effect they felt it might have
on their decision-making about mammography partici-
pation. The UK context is important ﬁrst, because of
the media attention there had already been to the over-
diagnosis issue at the time of this study1 21–23 and
second, because of the on-going and high-proﬁle criti-
cism of the information provided to women in the UK
about the breast screening programme.5 8 24 We focused
on the impact of relatively brief information on over-
diagnosis, to reﬂect the kind that might be provided in a
screening information leaﬂet.
METHODS
Methodological approach
Focus groups were used to explore women’s existing
knowledge and experience, and elicit dynamic responses
to potentially new information on overdiagnosis in the
context of a structured discussion.25 It is acknowledged
that focus groups are well suited to exploring ‘public’
topics, such as public health interventions26 and are a
good way to identify ‘group norms and cultural values’.25
We used focus groups rather than individual interviews for
this study to try to gauge the public response to informa-
tion about overdiagnosis in the context of a national
screening programme, and to provide participants with
the opportunity to question each other and to reﬂect and
respond to one another’s comments. A qualitative analysis
allowed us to identify common themes.
Participants
Six focus groups were conducted with women in the
mammography screening age range (50–71 years). All
women spoke ﬂuent English, none had a personal
history of cancer and none worked in occupations
related to cancer or cancer screening. Women living in
and around London were recruited from a specialist par-
ticipant recruitment agency, community groups, mailing
lists and adverts circulated by email to achieve a sample
with a range of ethnicities, and marital and socio-
economic status. Ethical approval was obtained (UCL
Research Ethics Committee: ref 3162/002).
Data collection
Groups were conducted in March and April 2012 at
UCL or a suitable community venue in London, and
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facilitated by an experienced qualitative researcher with
a second researcher acting as observer. In designing the
discussion guide, emphasis was placed on constructing
open-ended, non-directive questions and using a funnel-
ling approach with questions moving from the general
to the more focused (see online supplementary material
for the discussion guide).27 The aim was to generate dis-
cussion and elicit views on overdiagnosis. To open the
discussion, participants were invited to discuss their own
experiences of decision-making about mammography.
They were asked to read the relevant pages of the
current NHS breast screening leaﬂet28 to remind them
of the information currently provided about beneﬁts
and risks of screening, which includes a statement on
overdiagnosis (‘Screening can ﬁnd cancers which are
treated but which may not otherwise have been found
during your lifetime’). We then read out brief informa-
tion on overdiagnosis (see box 1) and women were
asked to discuss it and to consider how it might affect
their views of breast screening. The information was
repeated if participants requested this.
The description of overdiagnosis presented to the
focus groups was developed in consultation with experts.
We used 8 of 1000 cancer diagnoses as a starting
point, as this information is currently included in the
NHS leaﬂet.28 The range of 1–3 overdiagnoses of 8
cancers detected corresponds to a rate of overdiagnosis
of 12.5–37.5%, broadly consistent with the conclusions
of the UK review.7 The wording was designed to be
understandable to women of all educational back-
grounds. We used the term ‘slow-growing cancer’ rather
than overdiagnosis because it is familiar to the public
and has been used in previous overdiagnosis research.13
It also makes it very clear that overdiagnosis relates to
the detection of cancers and is therefore different from
false-positive results, as well as being distinct from the
treatment of benign conditions due to medical errors.
We chose to use brief information rather than a more
lengthy presentation, to reﬂect the level of detail women
might be given in a written leaﬂet.
Group discussions were digitally recorded and tran-
scribed verbatim. Participants also completed a short
questionnaire assessing demographic characteristics and
screening history.
Analysis
Verbatim transcripts were analysed thematically using
guidelines outlined by Braun and Clarke.29 Two
researchers read all the transcripts independently and
generated initial codes. These were then collated into
potential themes. A thematic map of the analysis was
produced by each researcher and these were reﬁned
through group discussion with all authors. All transcripts
were then re-read using the ﬁnal thematic map and
adjustments were made following further group discus-
sion. We used NVivo V.9 to code the data, and analysis
continued into the write-up stage using the themes and
verbatim examples to produce a narrative of women’s
experiences of the topic. Only sections of the analysis
concerned with overdiagnosis are reported here.
Demographic data were analysed using SPSS V.15.
RESULTS
A total of 40 women took part in six discussion groups;
the number of women per group ranged from four to
nine. Demographic characteristics of the sample are
shown in table 1. Focus groups lasted an average of
Table 1 Demographic characteristics of the sample
N (%)
Age (mean (SD); range) 58.5 (5.4); 50–71
Ethnic group
White 27 (67.5)
Black 6 (15.0)
Asian 5 (12.5)
Mixed 1 (2.5)
Other 1 (2.5)
Marital status
Married/cohabiting/civil partnership 15 (37.5)
Single/never married 12 (30.0)
Divorced/widowed 13 (32.5)
Highest level of education
University degree 21 (52.5)
A-levels/ONC/BTEC/other further
education
11 (27.5)
O-level or none 7 (17.5)
Missing 1 (2.5)
Time since last mammogram
3 years or less (as recommended) 29 (72.5)
4–9 years 4 (10.0)
10 years or more 3 (7.5)
Never screened 2 (5.0)
Screened, but time since last screen
missing
2 (5.0)
Ever called back for further tests?
Yes 5 (12.5)
No 33 (82.5)
N/A—never had a mammogram 2 (5.0)
Box 1 Description of overdiagnosis (read aloud to partici-
pants during group discussion)
It’s been suggested that some of the breast cancers that get diag-
nosed through breast screening are so slow-growing that they
would not have caused any problems. But because we can’t yet
tell which kind of cancer is the slow-growing kind, the woman
receives the usual treatment for breast cancer (eg, surgery). Of all
women who go for breast screening, about 8 in 1000 are diag-
nosed with cancer. It’s very hard to know what proportion of
cancers diagnosed in the screening programme are of the slow-
growing type and the experts disagree at the moment. The
estimates have varied from one in eight of women who are diag-
nosed to three in eight.
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75 min (range 51–93 min, depending on group dynam-
ics and how much women had to say about the issues
being discussed).
Themes emerged relating to women’s previous experi-
ences and beliefs about breast screening, and their atti-
tudes to false-positive results. As these issues are well
documented in the existing literature,15 30 31 we focus
here speciﬁcally on responses to the overdiagnosis infor-
mation (ie, Question 6 in the discussion guide—see
online supplementary material). Two main themes were
identiﬁed: (1) ‘Making sense of the concept of overdiag-
nosis’ and (2) ‘Implications of overdiagnosis informa-
tion’ (see box 2).
Making sense of the concept of overdiagnosis
In the initial discussions of mammography screening,
overdiagnosis was mentioned in four of six groups, but
there was only one group in which most women were
familiar with the concept. The few women who had
heard about the issue tended to ﬁnd it somewhat dis-
couraging and one said that negative information about
breast screening in the media, including on overdiagno-
sis, had inﬂuenced her intentions to attend.
I just haven’t felt like going again … I read everything
and there hasn’t been very good reports that I’ve read
recently, in the past ﬁve years basically, so I haven’t been
again. (P5)
After reading the information on the risks and bene-
ﬁts of breast screening in the NHS leaﬂet, some women
recalled seeing it before while others had little recollec-
tion of it and were unaware of the risk information. The
analysis here focuses on responses to the information in
box 1, which encompassed a number of themes.
Confusion
Some women found the statistical information on over-
diagnosis (box 1) difﬁcult to understand. The challenge
of making sense of the numerical information was impli-
cit in some participants’ responses but was also men-
tioned explicitly. In one group, participants struggled to
respond to the information that had been read to them:
P11: It’s hard to say really.
P10: I don’t know what to say about that.
P7: Yeah, it feels a bit, well, it’s only some, so, well, that’s
good because it’s only ﬁve [that need treatment] but I
don’t know. (Group 2)
Other women did demonstrate good understanding
though. In this group, one participant explained the
concept to another who was confused:
P15: I don’t understand
P19: No I don’t think she understands it a hundred per
cent.
P14: 8 women have cancer.
P15: Yes
P14: But maybe three, one two three… don’t have danger-
ous cancer. It doesn’t matter, they wouldn’t have died. They
would not have died without an operation. (Group 3)
Emotional responses
Some women expressed shock at the level of overdiagno-
sis and the implications for overtreatment, with women
in two of the groups voicing more concern about
unnecessary treatment than had been evident at earlier
stages of the discussion. Some said they would be angry
to discover that they had been unnecessarily treated for
cancer (‘I’d have their guts for garters’ (P7)). Others
highlighted the side-effects of treatment they had wit-
nessed in friends and family and expressed dismay at the
prospect of anyone having to go through that unneces-
sarily. There was also concern for the ﬁnancial cost
to the NHS and for the wasted time and energy of NHS
staff.
P27: I don’t know, but four out of ten! As you say one out
of ten is quite a lot. Four out of ten is horrendous.
P22: Scary!
P21: And I also think about the waste of funds and
resources when they could be used for people that genu-
inely need it … I’m quite shocked at what you’ve told me
today. (Group 4)
Cynicism
In ﬁve of the six focus groups, some cynicism was
expressed about the statistical information.
Well, I’m very sceptical about statistics generally because
I’ve seen them manipulated to prove what the person
using them wishes to prove. (P2)
In particular, some women feared that statistical data
supporting the risks of mammography could be used to
justify a cost-cutting exercise in which the NHS Breast
Box 2 Thematic structure
1. Making sense of the concept of overdiagnosis
▸ Confusion
▸ How do they know?
▸ Emotional responses
▸ Cynicism
▸ Referring to experts
2. Implications of overdiagnosis information
▸ Erring on the side of caution
▸ Right to know
▸ Overdiagnosis as a treatment issue
▸ Impact on screening decisions
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Screening Programme might be restricted or withdrawn.
Many women became protective of the screening pro-
gramme at this stage in the face of what was perceived to
be a threat to the service.
I would hate to see funding for screening of breast
cancer being removed because, even though I might not
go for it, it’s a choice and it’s good to have the choice,
and I think that choice is very, very important and such a
vital thing you know. (P3)
Referring to experts
Once women had an understanding of the concept of
overdiagnosis they began to refer to experts in two ways:
ﬁrst to question how scientists know that this phenomenon
exists and then to express their trust in health experts.
Women often questioned the statistical information
they had been given.
How do they know? How have they arrived at those
ﬁgures, then? Because is it just literally at the end of
chemo, they go ‘Yeah, it’s still there, or no, it’s…?’ (P22)
When it was explained that an individual woman
would not know that her treatment had been unneces-
sary, participants began to question the basis of the
information. Where women asked these questions, facili-
tators explained that statistical modelling is used to esti-
mate levels of overdiagnosis. Not surprisingly, many
participants found this difﬁcult to understand.
I mean if this is all done on modelling, what’s it mod-
elled on? Is it that when they remove things they ﬁnd dif-
ferent things within it, but you have to have it removed to
know that? … Or is it that it’s all coming through post-
mortems and things? (P27)
Some participants wondered if doctors would choose
not to treat a suspected slow-growing cancer, alluding to
an implicit fear of undertreatment.
Because doctors aren’t infallible are they? … Some will
be more cautious than others, some will want to err on
the side of not doing very much surgery and only doing
as little as they can get away with until there is an indica-
tion that more is needed. (P37)
Others felt that surgeons ‘like to wield their knives’
(P19) and might be inclined to operate rather than try
alternative approaches.
However, there was also widespread trust in health
experts, which was expressed in all groups. There was
trust in doctors, scientists and the NHS breast screening
programme to utilise new knowledge or improved tech-
nology to ameliorate the risk of overdiagnosis and
unnecessary treatment in the future.
P5: I think that my having heard all this now, I mean [I
am] more educated about it and I would say now that I
just have a trust that the NHS wouldn’t haul us all out if
statistically there wasn’t some evidence that, by and large,
some people get saved, you know, and that not many
people get disadvantaged.
P4: I have some trust to some extent because I think it’s
evidence-based treatment, isn’t it? (Group 1)
Implications of overdiagnosis information
Erring on the side of caution
As women discussed the implications of the information
about overdiagnosis, a broad consensus emerged that over-
diagnosis and false positives were strongly preferred to any
risk of underdiagnosis. Some women saw overdiagnosis
and false positives as evidence that the screening pro-
gramme was thorough in its detection of cancer. False posi-
tives in this context were considered to be acceptable
despite the short-term worry of being recalled, of which
some women had personal experience. In contrast,
women were extremely concerned about false negatives
and the risk that cancer might be missed or treatment
delayed.
Well for me it’s life or death, really, so there is no ques-
tion that I would want to go for screening and have treat-
ment as appropriate, because there are unknowns. We
don’t know if it is fast growing or slow growing. So I
would want to have treatment with advice and stay alive
basically. (P37)
Right to know
There was, however, a strong belief that women should
be given information about overdiagnosis. Participants
felt the information should be ‘part of my decision’ to
attend for screening and, in the event of a breast cancer
diagnosis, to be part of their decision about treatment.
One participant talked about informed decision-making:
Yes but it’s a question of … awareness. It’s a question of
giving us the information … And letting us process it our-
selves and letting us make an informed decision. The
facts. (P19)
Another recognised the variation in the amount of
information that different people might want:
You can’t deny people who want to know just because
others don’t. (P26)
Overdiagnosis as a treatment issue
Many women struggled to see information on overdiag-
nosis as relevant to their decision-making about screen-
ing. Much of the discussion was around treatment
decisions for screen-detected cancers. Women were con-
cerned about unnecessary treatment but were also keen
to treat cancer.
I mean, just think, they would say to you ‘You’ve got it
but we don’t think it’s going to come to anything and so
you don’t have to have treatment if you don’t want to’.
That doesn’t make sense to me. If someone says ‘You’ve
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got a cancer’, you say ‘Right, let’s do something about it.’
(P34)
In general, the risk of undertreatment of cancer was
seen as much greater than the risk of overtreatment.
Impact on screening decisions
At the end of the groups, most women retained their
initial perspectives on attending screening. Previous
attenders maintained that ‘I’d still have a mammogram,
yeah’. The reasons cited included reassurance that they
do not have cancer, a desire to know if cancer is present
and to increase the chances of an earlier diagnosis and
more successful treatment. The information on over-
diagnosis did not seem to have affected their core
beliefs about screening.
I would still go, you know, it’s better knowing than not
knowing… At least I know that, it gives me time to plan
… things or what to do next. So I would rather have it
done. It wouldn’t change my view at all. (P17)
Despite the majority of screening decisions being
unaffected, a few women did describe a change in attitude.
One participant who initially described mammograms as
‘very good’ and ‘very important’ responded to the over-
diagnosis information by saying ‘That puts you off going at
all doesn’t it?’ and later ‘I ﬁnd that very worrying, to have
an operation when you didn’t need to’ (P12). Another
who had recently attended for screening said
I’m in the clear at the moment [because of just having
been screened] and I’m wondering whether I do want to
go again actually. (P40)
Women who had never attended screening or had
ceased to attend also tended to maintain their view
although, perhaps surprisingly, one woman thought that
following the discussion, she would consider attending
in future.
As I said, I haven’t had an invitation for so many years
that it is something that you don’t even think about really
… so I, you know, will gather … more information and
make another informed decision about whether I will or
not go. I mean it’s my choice at the end of the day so no
one can force me to go there … I will have another
think about it seriously. (P19)
DISCUSSION
In this qualitative study, we identiﬁed widespread lack of
awareness of the risk of overdiagnosis in breast cancer
screening among screening-eligible women. When pro-
vided with information about the range of risks of over-
diagnosis and unnecessary treatment, they were often
shocked and surprised, initially. After these initial emo-
tional responses, many women went on to question the
basis of the estimates of overdiagnosis, sometimes
expressing scepticism but usually trusting health
professionals to make appropriate decisions. Most of
those who had previously participated in screening
maintained a positive attitude to the programme, prefer-
ring the risk of overtreatment to the risk of undertreat-
ment. Given that no individual would know that her
treatment had been unnecessary, women expressed an
overwhelming preference to err on the side of caution.
Some also regarded the information as relevant to
choices about treatment rather than screening. In a few
cases, however, women were put off by the information
and felt that it might deter them from future screening
attendance. Our ﬁndings are strikingly similar to a
recent Australian study,20 despite differences in the way
that information on overdiagnosis was presented. This
suggests that similar communication challenges will be
faced across countries where breast screening is offered.
The study beneﬁtted from the inclusion of women
within the breast screening age range, around 70% of
whom had been screened within the last 3 years, which is
broadly in line with national coverage data.32 Women
willing to attend a discussion group on mammography
may generally be more proscreening than the general
population and this may be a limitation of our study,
although this concern is mitigated by the fact that our
groups included women in the screening age range who
had never attended or were overdue for screening. The
use of focus groups allowed the complex issues surround-
ing overdiagnosis to be explored and discussed within a
group context, enabling us to understand more about
likely public responses to information within the screening
programme than would be possible using individual inter-
views. However, individual interviews may have been more
informative in understanding women’s individual
responses and the way that information might be inte-
grated into women’s screening histories and experiences.
Larger-scale work will be needed to establish the generalis-
ability of the ﬁndings. In common with most qualitative
research, we used non-random sampling, recruiting
women using a range of methods. This, and the fact that
women were recruited in and around London, may also
limit the generalisability of our ﬁndings.
Our participants sometimes found it difﬁcult to under-
stand the brief explanation of overdiagnosis that we pro-
vided, and there is an urgent need to develop clear and
concise methods of conveying both the concept and its
prevalence in a written format to provide to women.
The difﬁculties of communicating risk estimates to the
lay public are well documented33 but may be particularly
challenging where epidemiological, clinical and lay per-
spectives differ34 and where there is such wide disagree-
ment between experts.
We chose to use the term ‘slow-growing’ to describe
cancers that are overtreated in the screening programme
as this has been used in previous survey work.13 There is
on-going debate about how best to communicate the
concept of overdiagnosis to a lay audience. The citizen’s
jury carried out as part of the current review of NHS
information materials found that women preferred the
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term ‘overtreatment’ to ‘overdiagnosis’,35 while the
recent Australian study20 used ‘overdetection’ (both
these were published after our study had been com-
pleted). To our knowledge, no empirical data are avail-
able on the impact that using these different terms has
on responses to the information. However it is possible
that the image of a slow-growing cancer could have led
our participants to think about receiving a cancer diag-
nosis and may have caused them to focus on treatment
rather than screening decisions. The terms ‘overdetec-
tion’ and ‘overdiagnosis’ may make it easier to consider
the concept in more abstract terms. But we felt it was
important for women to realise that the cancers being
overdiagnosed in the screening programme do repre-
sent malignant disease, as distinct from false-positive
results. Further research is needed to identify the best
way to describe the phenomenon.
The themes we identiﬁed included some that have
been described before. We found that women had a
desire to be provided with all the available information
on risks,17 although this was tempered by concern that
risk information may put ‘other people’ off screening.18
The theme of viewing others as being more risk averse
or easily deterred has been found in other qualitative
studies18 and it is unclear whether this is a coded way of
expressing personal concern or a reﬂection of broader
identity beliefs that tend to represent the self as stronger
than others in many respects. There is evidence that
people evaluate risk differently when considering them-
selves and when considering others, tending to be more
risk averse when considering other people.36 It is pos-
sible, therefore, that women in our study were cautious
of anything that might deter others from attending
screening. Some women also expressed scepticism about
any suggestion of shortcomings of mammography, which
is consistent with the ﬁnding that even women with
interval cancer diagnoses tend to maintain trust in the
screening programme and to see their own cases as
exceptions to an otherwise effective programme.37
The ﬁnding that women generally preferred to be
overdiagnosed than underdiagnosed is consistent with
previous survey ﬁndings of high tolerance levels of false-
positive results15 and a fear of false-negative results iden-
tiﬁed in qualitative work38; in other words women
appear to value sensitivity over speciﬁcity, which has
been found in qualitative studies in other screening as
well as diagnostic contexts.39 40 But this is the ﬁrst study,
to our knowledge, to have explicitly explored the notion
of overdiagnosis in the UK breast screening context.
The study has two broad implications. First, it highlights
the difﬁcultly of communicating the concept of overdiag-
nosis to non-statisticians. Confusion was common and
women found the idea that the estimates of overdiagnosis
are based on statistical modelling extremely difﬁcult to
understand. Further work is needed to develop ways of
conveying this type of information clearly, especially given
moves towards a policy of informed choice in screening.41
Second, although women felt the information was
important, it generally had little impact on their beliefs
about screening and their future intentions to participate.
More work will be needed to see whether this ﬁnding
could be generalised to the wider population and whether
the impact of information on overdiagnosis differs across
socioeconomic groups.
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